Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study

Abstract

Substantial clinical and economic burden exists among individuals with NET treated with medical or surgical therapies. Future research should investigate this treated sub-population considering a longer follow-up due to slow disease progression.

Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors

“…This adds to the already considerable financial burden associated with surgical or medical therapy for NET management. 6 A retrospective study reported that monthly total health care costs of NET patients in the United States who were treated with medical therapy increased from $5629.70 in the 6 months preceding the diagnosis to $9093.30 in the 12 months following (an increase of more than 60%). For those receiving surgical therapy, the costs increased from $2547.90 to $8810.40 in the 6 months before and 12 months after the diagnosis, respectively.…”

“…For those receiving surgical therapy, the costs increased from $2547.90 to $8810.40 in the 6 months before and 12 months after the diagnosis, respectively. 6 …”

“…The wide array of imaging techniques, biochemical testing, and expertise that are required to characterize the location and grade of the primary tumor and the extent of metastatic disease could possibly lead to patients receiving conflicting treatment plans and misdiagnoses. 4,5 A large number of health care resources are also required for the long-term management of NETs, 6,7 with qualitative studies highlighting the lack of a clear pathway of care for patients with NETs. 8,9 Neuroendocrine tumor management should be highly individualized based on the burden and symptoms associated with the tumor and whether the aim of treatment is to ameliorate symptoms or prevent tumor growth.…”

“…9 A substantial financial burden has also been demonstrated in NET patients in the United States, particularly in the first year after receipt of the diagnosis and regardless of whether the patients received surgery or medical therapy. 6 Although NETs have been shown to have a clear impact on patients' lives in North America, the patient perspective is not well documented, and the use of disease-specific quantitative surveys may provide further insight into the individual symptoms and concerns associated with NETs. 13,14 …”

Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study

“…In addition to characterizing the various treatments, dose data for octreotide, the most common SSA treatment in this study, were analyzed, and the analysis showed most octreotide administrations were given at the standard dose of 30 mg/4 weeks for CS treatment. Furthermore, whereas prior studies on resource use for patients with NET have focused on all‐cause use , this study adds to the literature by showing lung NET‐related resource use following advanced lung NET diagnosis.…”